· The sickle cell disease segment held the largest share of 58.61% of the market in 2024 · The sickle cell disease diagnosis segment dominated the market and accounted for a 50.46% share in 2024 and ...

Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate ...

Novo Nordisk expects Mim8 regulatory submission during 2025. Data from the ongoing phase 3 FRONTIER program will be disclosed at upcoming congresses and in publications in 2025 and 2026.

Novo Nordisk expects Mim8 regulatory submission during 2025. Data from the ongoing phase 3 FRONTIER program will be disclosed at upcoming congresses and in publications in 2025 and 2026. In September ...

Elsewhere in the hemophilia space, Novo Nordisk earlier this month reported that its bispecific antibody Mim8 reduced bleeding events in pediatric patients. The pharma is preparing for regulatory ...

In the FRONTIER3 trial, 74.3% of children receiving once-weekly Mim8 prophylaxis experienced zero treated bleeds. Mim8, an investigational factor VIIIa mimetic bispecific antibody, demonstrated ...

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro talks about the challenges faced in developing T cell engagers. Ian Chan, CEO of Abpro, discusses the advantages of ...

Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments. Results from the Phase III FRONTIER3 trial found that Novo Nordisk’s Mim8 ...